Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies
- PMID: 27798074
- PMCID: PMC5412015
- DOI: 10.1093/jat/bkw114
Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies
Abstract
The legalization of marijuana in the USA for both medicinal and recreational use has increased in the past few years. Currently, 24 states have legalized marijuana for medicinal use. The US Drug Enforcement Administration has classified marijuana as a Schedule I substance. The US Food and Drug Administration does not regulate formulations or packages of marijuana that are currently marketed in states that have legalized marijuana. Marijuana edibles or "medibles" are typically packages of candies and baked goods consumed for medicinal as well as recreational marijuana use. They contain major psychoactive drug in marijuana, delta-9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD), which has reputed medical properties. Presented is a method for the preparation and application of THC and CBD containing brownies used as quality control (QC) material for the analysis of marijuana or cannabinoid baked medibles. The performance parameters of the assay including possible matrix effects and cannabinoid stability in the brownie QC over time are presented. It was determined that the process used to prepare and bake the brownie control material did not degrade the THC or CBD. The brownie matrix was found not to interfere with the analysis of a THC or a CBD. Ten commercially available brownie matrixes were evaluated for potential interferences; none of them were found to interfere with the analysis of THC or CBD. The laboratory baked medible QC material was found to be stable at room temperature for at least 3 months.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Figures
References
-
- Title 21, United States Code, Controlled Substances Act, Chapter 13, Subchapter 1, Part B, Section 812. Schedule of Controlled Substances, 2012.
-
- Friedman D., Devinsky O. (2015) Cannabinoids in the treatment of epilepsy. The New England Journal of Medicine, 373, 1048–1058. doi:10.1056/NEJMra1407304. - DOI - PubMed
-
- Johnson J.R., Burnell-Nugent M., Lossignol D., Ganae-Motan E.D., Potts R., Fallon M.T. (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management, 39, 167–179. doi:10.1016/j.jpainsymman.2009.06.008. - DOI - PubMed
-
- Manseau M.W., Goff D.C. (2015) Cannabinoids and schizophrenia: risks and therapeutic potential. Neurotherapeutics, 12, 816–824. doi:10.1007/s13311-015-0382-6. - DOI - PMC - PubMed
-
- Orens A., Light M., Rowberry J., Matsen J., Lewandowski B. Marijuana Equivalency in Portion and Dosage: An assessment of physical and pharmacokinetic relationships in marijuana production and consumption in Colorado. Colorado Department of Revenue, August 10, 2015.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous